（记者 贾运可） 每经AI快讯，新诺威9月30日晚间发布公告称，公司拟以现金购买恩必普药业持有的巨石生物29%股 权。本次交易以符合《证券法》规定的评估机构出具的资产评估报告中的评估结果作为定价依据，最终 确定本次交易标的股权的转让价款为110000万元。本次交易完成后，公司持有巨石生物的股权比例将由 51%增加至80%。 每经头条（nbdtoutiao）——前脚消费贷，后脚被银行追讨发票，7天内上传，否则后果严重！有人为此 焦虑，有人却趁机牟利：帮开票包过审 ...

证券代码：300765 证券简称：新诺威 公告编号：2025-074 石药创新制药股份有限公司 关于现金收购控股子公司石药集团巨石生物制药有限公司 部分少数股权暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、石药创新制药股份有限公司（以下简称"公司"、"上市公司"、"石药创新"） 拟以现金购买石药集团恩必普药业有限公司（以下简称"恩必普药业"）持有的石 药集团巨石生物制药有限公司（以下简称"巨石生物"或"标的公司"）29%股权（以 下简称"本次交易"）。本次交易完成后，公司持有巨石生物的股权比例将由 51% 增加至 80%。 2、本次交易以符合《证券法》规定的资产评估机构出具的资产评估报告中 的评估结果作为定价依据，最终确定本次交易标的股权的转让价款为 110,000.00 万元。 | | 本次交易前 | | | 本次交易后 | | | --- | --- | --- | --- | --- | --- | | 股东 | 出资额（万元） | 持股比例 | 股东 | 出资额（万元） | 持股比例 | | 石药创新 | 104,0 ...

从基金十大重仓股角度 数据显示，交银施罗德基金旗下1只基金重仓新诺威。交银医药创新股票A（004075）二季度减持65.1万 股，持有股数233.73万股，占基金净值比例为4.66%，位居第五大重仓股。根据测算，今日浮亏损失约 308.53万元。连续3天下跌期间浮亏损失1154.64万元。 交银医药创新股票A（004075）成立日期2017年3月23日，最新规模25亿。今年以来收益40.44%，同类 排名1107/4221；近一年收益46.06%，同类排名1688/3836；成立以来收益200.9%。 9月29日，新诺威跌2.76%，截至发稿，报46.47元/股，成交3.34亿元，换手率0.58%，总市值652.71亿 元。新诺威股价已经连续3天下跌，区间累计跌幅9.61%。 交银医药创新股票A（004075）基金经理为楼慧源。 资料显示，石药创新制药股份有限公司位于河北省石家庄市栾城区张举路62号，成立日期2006年4月5 日，上市日期2019年3月22日，公司主营业务涉及功能食品的研发、生产与销售。主营业务收入构成 为：功能食品及原料88.93%，生物制药8.91%，其他2.16%。 截至发稿，楼慧源累计 ...

9月25日，市场震荡上行，创业板指探底回升一度涨逾2%，续创3年多新高。截至收盘，沪指跌0.01%， 深成指涨0.67%，创业板指涨1.58%。沪深两市成交额2.37万亿，较上一个交易日放量443亿。板块方 面，游戏、AI应用、可控核聚变等板块涨幅居前，港口航运、贵金属、油气等板块跌幅居前。 | 名称 | 最新点位 | 涨跌幅 | | --- | --- | --- | | 上证指数 | 3853.3 | -0.34(-0.01%) | | 深证指数 | 13445.9 | +89.76(0.67%) | | 创业板指 | 3235.76 | +50.19(1.58%) | | | 日期:9月25日 制图:21投资通 | | 隔夜外盘 纽约股市三大股指9月25日集体下挫。截至当天收盘，道琼斯工业平均指数比前一交易日下跌173.96 点，收于45947.32点，跌幅为0.38%；标准普尔500种股票指数下跌33.25点，收于6604.72点，跌幅为 0.50%；纳斯达克综合指数下跌113.16点，收于22384.70点，跌幅为0.50%。 欧洲三大股指9月25日全线下跌。截至当天收盘，英国富时100种股票平均价 ...

Group 1: Regulatory Actions - The National Healthcare Security Administration (NHSA) has launched a "100-day action" to address prominent issues in medical insurance fund management, aiming to combat fraud and illegal activities related to the resale of medical insurance drugs [1] - The initiative reflects a zero-tolerance approach towards fraudulent practices, which may increase compliance pressure on medical institutions and pharmaceutical companies in the short term, while potentially purifying the industry ecosystem in the long run [1] Group 2: Company Developments - Hanyu Pharmaceutical plans to raise up to 968 million yuan (approximately 136 million USD) through a private placement to fund various projects, including the research and development of Semaglutide [2] - The approval of Lunacanab by XinNuoWei for clinical trials marks the first domestic biosimilar drug for Alzheimer's disease, which could enhance patient accessibility and alleviate financial burdens [3] - Baile Tianheng's ADC dual antibody, Iza-bren, has been included in the breakthrough therapy list by the National Medical Products Administration, which may expedite its market entry and positively impact the company's stock price [4] - Tainkang's subsidiary has received approval for clinical trials of CKBA cream for rosacea, filling a gap in the domestic market for innovative treatments in this area [5]

Group 1 - The National Healthcare Security Administration (NHSA) has launched a "100-day action" to crack down on fraudulent medical insurance practices, aiming to eliminate illegal activities such as the resale of returned drugs by designated institutions [1] - This initiative reflects a zero-tolerance approach towards fraud and is expected to increase compliance pressure on medical institutions and pharmaceutical companies in the short term, ultimately helping to purify the industry ecosystem [1] Group 2 - Hanyu Pharmaceutical plans to raise up to 968 million yuan (approximately 136 million USD) through a private placement to fund projects including the development of Semaglutide, which is part of the GLP-1 drug class with significant market potential [2] - If the fundraising is successful, it will accelerate the company's GLP-1 drug development process and enhance its production capacity for peptide raw materials [2] Group 3 - XinNuoWei announced that its subsidiary received approval for clinical trials of Lecanemab, a monoclonal antibody drug for treating Alzheimer's disease, marking it as the first domestic biosimilar of this drug to gain clinical approval [3][4] - The approval of this biosimilar is expected to improve patient accessibility and alleviate financial burdens, as current treatments for Alzheimer's are predominantly high-priced products from multinational companies [4] Group 4 - Baillie Tianheng's ADC dual antibody drug, Iza-bren, has been included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) for treating advanced or metastatic urothelial carcinoma that has failed previous treatments [5] - This designation is likely to expedite the drug's market entry and could positively impact the company's stock price in the short term [5] Group 5 - Tainkang's subsidiary has received approval for clinical trials of CKBA cream for the treatment of rosacea, a first-class innovative drug in China for this condition [6][7] - The approval of this innovative drug could fill a gap in the domestic market for rosacea treatment, presenting considerable market potential if clinical trials demonstrate its efficacy [7]

Group 1: Investment and Fundraising - Hanyu Pharmaceutical plans to raise no more than 968 million yuan for the development of semaglutide and other projects [1] - Ganfeng Lithium intends to introduce investors for a capital increase of up to 2.5 billion yuan [9] Group 2: Strategic Restructuring - Pingmei Shenma Holdings is undergoing a strategic restructuring as directed by the Henan provincial government, which will not affect the company's operations significantly [2][8] - Shennong Holdings is also involved in a strategic restructuring with no change in control or significant impact on operations [7][8] Group 3: Clinical Trials and Approvals - XinNuoWei's subsidiary received approval for clinical trials of a drug for treating mild Alzheimer's disease, marking a significant milestone in the development of biosimilar drugs [3] - Tainkang's subsidiary has received approval for clinical trials of CKBA cream for rosacea, a first-class innovative drug in China [4] - Baili Tianheng's drug, iza-bren, has been included in the list of breakthrough therapies, indicating its potential in treating advanced urinary tract cancer [5] Group 4: Contracts and Projects - Zhongyou Engineering signed an EPC contract worth 2.524 billion USD for a seawater pipeline project in Iraq, expected to positively impact future revenues [6]

Group 1 - The core point of the article is that New Horizon announced the approval of a clinical trial for a drug called Lankanaib injection by the National Medical Products Administration [2] Group 2 - The approval was granted to the company's subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. [2]

Core Viewpoint - New Horizon (300765) announced that its subsidiary, Shijiazhuang Yiling Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of Lecanemab injection, marking it as the first in China to obtain such approval for this drug [1] Group 1 - The product is a recombinant anti-human beta-amyloid monoclonal antibody drug, classified as a biosimilar to Lecanemab [1] - It is submitted under the category of therapeutic biological products 3.3, aimed at treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [1] - The clinical trial is set to commence shortly following the approval [1]

Core Viewpoint - XinNuoWei's subsidiary, JuShi Bio, has received approval from the National Medical Products Administration for clinical trials of Lunkanaib monoclonal antibody injection, marking a significant milestone in the treatment of Alzheimer's disease-related cognitive impairment and mild dementia [1] Company Summary - JuShi Bio is the first in China to obtain clinical approval for Lunkanaib monoclonal antibody injection, a biosimilar drug [1]